Current candidate biomarkers for CN include miR-126 and miR-145 that inhibit the growth of CN cells by targeting the phosphatidylinositol 3-kinase signaling and the insulin receptor substrate-1, respectively36,37. This evidence concerns the gene IRS1 and cyclic hematopoiesis.